TM Owner Novartis
Trametinib 2mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- The sheet lists this product under the generic/molecule name 'Trametinib' rather than a marketed brand; the actual approved brand for this 2 mg tablet (formulated as trametinib dimethyl sulfoxide) is Mekinist, currently marketed by Novartis.
- Mekinist is a MEK inhibitor approved, as a single agent or in combination with dabrafenib (Tafinlar), for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, and for adjuvant treatment after surgery for BRAF-mutated melanoma.
- The dabrafenib-trametinib combination is also approved for BRAF V600E-mutated metastatic non-small cell lung cancer, anaplastic thyroid cancer, and certain BRAF V600E solid tumours and low-grade gliomas in children.
- Treatment is specialist-initiated (oncology) but the tablets are taken by the patient at home once started.
Side Effects
- Mekinist (trametinib) has NO boxed warning.
- Very common effects include rash, dry skin, diarrhoea, nausea, swelling of the hands, feet or face (peripheral oedema), fatigue and joint or muscle pain.
- Serious reactions to watch for include signs of heart problems (new breathlessness, ankle swelling, palpitations - heart function is checked before and during treatment); eye problems such as blurred vision, loss of vision or seeing halos, which can indicate retinal vein occlusion or fluid under the retina and need prompt eye examination; new or worsening cough and breathlessness, which can signal lung inflammation; unusual bleeding or bruising; and skin infections at sites of rash.
- When combined with dabrafenib, a distinct fever reaction (sometimes with chills and dizziness) can occur and should be reported promptly so treatment can be paused if needed.
Precautions & Warnings
- Mekinist can cause serious harm to an unborn baby, so effective contraception is required during treatment and for 4 months after the final dose in anyone who could become pregnant, and men are also advised on contraception; it should not be used in pregnancy or while breastfeeding.
- Heart function (left ventricular ejection fraction) is checked before starting and periodically during treatment, and Mekinist may need to be paused or stopped if it falls.
- An eye examination is needed if any visual disturbance occurs.
- Tablets must be swallowed whole, one hour before or two hours after food, and never crushed or chewed; if a bottle contains a desiccant packet, it must stay in the bottle and not be swallowed.
- Tell your care team about any fever, especially if you also take dabrafenib, and about any planned surgery or dental work because of bleeding and wound-healing risks.
Avoid Interactions
- Trametinib itself is broken down mainly by de-acetylation rather than by the liver's major CYP450 enzymes, so it has few well-established drug-drug interactions of its own; even so, tell your oncology team about every prescription, over-the-counter and herbal medicine you take.
- When trametinib is combined with dabrafenib, the interaction profile is driven mainly by dabrafenib, which does interact significantly with many CYP3A4- and CYP2C8-related medicines, hormonal contraceptives and QT-prolonging drugs, so your combination regimen carries its own separate interaction checklist from your oncology pharmacist.
- Grapefruit and grapefruit juice are best avoided as a general precaution with oral targeted cancer therapies.
- Because Mekinist increases bleeding risk, caution is needed with anticoagulants and antiplatelet medicines, and this should be discussed before any dose changes.
References
Frequently Asked Questions
Trametinib is marketed as Mekinist. It treats BRAF-mutated melanoma, alone or with dabrafenib, including after surgery to prevent recurrence. The dabrafenib-trametinib combination also treats certain BRAF-mutated lung cancers, thyroid cancers, and tumours in children. It targets a specific cancer-driving mutation, so genetic testing confirms eligibility first.
Mekinist 2 mg tablets are swallowed whole, once daily, on an empty stomach - one hour before or two hours after food. Never crush or chew them. Take it at the same time each day and keep the desiccant packet in the bottle.
Common side effects of Mekinist include rash, dry skin, diarrhoea, swelling and tiredness. Report new breathlessness, ankle swelling, vision changes, or a cough right away, as these can signal heart, eye or lung problems that need prompt checking. There is no boxed warning.
Avoid pregnancy while taking Mekinist (trametinib) - effective contraception is needed during treatment and for 4 months afterwards. Avoid grapefruit as a general precaution. Tell your oncology team about all other medicines, especially if you also take dabrafenib, which has its own interactions.
Yes. Mekinist can affect heart pumping function and the retina, so your care team checks heart function (an echocardiogram) before starting and periodically during treatment, and arranges an eye exam if you notice any blurred vision, halos or vision loss.
Not quite - trametinib is the generic (molecule) name; the approved brand for this tablet is Mekinist, made by Novartis. Ask your pharmacist to confirm your dispensed product is Mekinist or an approved generic trametinib if the packaging only shows the generic name.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
